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Abstract 30 
In relation to emerging multiresistant bacteria, development of antimicrobials and new 31 
treatment strategies of infections should be expected to become a high priority research 32 
area. Quorum Sensing (QS), a communication system used by pathogenic bacteria like 33 
Pseudomonas aeruginosa to synchronise the expression of specific genes involved in 34 
pathogenicity, is a possible drug target. Previous in vitro and in vivo studies revealed a 35 
significant inhibition of P. aeruginosa QS by crude garlic extract. By bioassay-guided 36 
fractionation of garlic extracts we determined the primary QS inhibitor present in garlic 37 
as ajoene, a sulfur-containing compound with potential as an antipathogenic drug. By 38 
comprehensive in vitro and in vivo studies of the effect of synthetic ajoene towards P. 39 
aeruginosa was elucidated. DNA microarray studies of ajoene treated P. aeruginosa 40 
cultures revealed a concentration dependent attenuation of a few, but central QS 41 
controlled virulence factors including rhamnolipid. Furthermore, ajoene treatment of in 42 
vitro biofilms demonstrated a clear synergistic, antimicrobial effect with tobramycin on 43 
biofilm killing and a cease in lytic necrosis of polymorphonuclear leukocytes. 44 
Furthermore, in a pulmonary infectious mouse model a significant clearing of infecting P. 45 
aeruginosa was detected in ajoene-treated mice compared to a non-treated control group. 46 
 3
This study adds to the list of examples demonstrating the potential of QS interfering 47 
compounds in the treatment of bacterial infections.  48 
 49 
Introduction 50 
Infections that develop into chronic conditions are a fast growing problem in the 51 
developed world. The underlying biology is thought to be the ability of bacteria to form 52 
biofilms (20) which consist of structured and aggregated (often surface-attached) 53 
communities of bacteria (18). Multiple studies have documented that such aggregated 54 
communities are more resistant to a variety of antibiotics and the action of the immune 55 
system compared to their planktonic counterparts (6, 19, 41, 68). Biofilm infections are 56 
often connected to patients with medical devices and implants as well as hospitalized 57 
patients. Lately bacterial biofilms have also been associated with non-healing, chronic 58 
wounds (9, 24, 38). There is thus an urgent need for development of new treatment 59 
strategies using a combination of drugs targeting a multitude of antimicrobial targets. 60 
Several Gram-negative pathogens use N-acyl homoserine lactones (AHLs)-mediated 61 
communication systems in a process termed quorum sensing (QS) to coordinate specific 62 
gene expression, thereby synchronizing expression of particular phenotypic features 63 
between the individual cells (28). QS is thought to play an important role during the 64 
initial event of infection for the common opportunistic Gram-negative human pathogen 65 
Pseudomonas aeruginosa, which is associated with nosocomial and wound infections, 66 
immunocompromised (48, 70) and the genetic inherited disease cystic fibrosis (CF) (22). 67 
By employing the QS system to control expression of its virulence factors (many of 68 
which are antigenic determinants), P. aeruginosa is able to operate in a stealthy manner 69 
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until a certain cell density is reached where the QS systems become activated. Upon 70 
activation of the QS systems, a coordinated release of tissue damaging and immune 71 
defense degrading virulence factors takes place (28, 36). It was recently documented by 72 
us that the QS controlled virulence factor rhamnolipid (also known as heat-stable 73 
hemolysin) destroys polymorphnuclear (PMN) leukocytes by lytic necrosis (36). Besides 74 
lysing neutrophils and macrophages, rhamnolipid has also been reported to impair 75 
chemotaxis of neutrophils (42, 62). As rhamnolipid is associated with bacteria living in 76 
biofilm, it is likely to function as a shield towards important cellular components of the 77 
host defense (1, 36, 71). Furthermore, QS promotes increased tolerance of P. aeruginosa 78 
biofilms to antibiotic treatments (6) and provides biofilms with structural rigidity through 79 
release of eDNA (21, 56).  80 
Two of the P. aeruginosa quorum sensors are based on the LuxRI homologues present in 81 
most Gram-negative bacteria with QS systems. The I homologues function as an AHL 82 
synthetase producing the required signal molecules and the R homologues function as 83 
transcriptional activators which upon binding of the cognate signal molecules activate the 84 
transcription of the QS target genes (28). The P. aeruginosa QS system consists of lasRI 85 
and rhlRI hierarchically arranged with the las encoded system normally at the top level 86 
controlling the rhl encoded system and a third system intervened in between the two 87 
denoted the pseudomonas quinolone signal (PQS). The three interacting QS systems 88 
LasRI, RhlRI and PQS use the following signal molecules for activation, N-(3-89 
oxododecanoyl)-L-homoserine lactone (3-oxo-C12-HSL), N-butanoyl homoserine 90 
lactone (C4-HSL) and 2-heptyl-3-hydroxy-4-quinolone (PQS), respectively (50, 51, 54).  91 
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It has been shown that some terrestrial and marine organisms have evolved a production 92 
of specific molecules with AHL-antagonistic activity capable of interfering with the 93 
bacterial QS system in a possible prevention of colonization (8, 55, 58, 59, 64). Hentzer 94 
et al. (33) and Wu et al. (76) demonstrated that the QS system could be used as an 95 
effective antimicrobial drug target by altering the tolerance of biofilms to antibiotic 96 
treatment and promote a faster clearance of a P. aeruginosa lung infection in mice by 97 
using the chemically modified QS inhibitor (QSI) furanone C-30. Crude extracts of garlic 98 
(Allium sativum L) have been shown to inhibit the expression of a large number of QS 99 
controlled genes (58) and Bjarnsholt et al. (8), demonstrated the ability of garlic extracts, 100 
similar to C-30 treatments, to promote a rapid clearing of a pulmonary P. aeruginosa 101 
infection in mice. Garlic is widely accepted as a herb that through a dietary intake can 102 
improve human health (61). Epidemiological studies have shown that a daily intake of 103 
garlic lowers the risk of certain cancers (25, 63) and several studies have documented an 104 
antithrombotic and lipid lowering cardiovascular effect of some of the constituents in 105 
garlic (27). 106 
By means of a bioassay directed purification procedure, we identified the sulfur 107 
containing compound ajoene (4,5,9-trithiadodeca-1,6,11-triene 9-oxide) as a QSI present 108 
in garlic extract. When garlic is crushed, ajoene and several other organosulfides are 109 
produced as degradation products of allicin (diallyl thiosulfinate) (11). Ajoene has been 110 
reported to display conventional antimicrobial activities to a number of Gram-positive 111 
bacteria and the Gram-negative bacteria Escherichia coli, Klebsiella pneumoniae and 112 
Xanthomonas maltophilia but not P. aeruginosa (45). To further exploit the QSI activity 113 
in vitro and in vivo, we employed chemically synthesized ajoene (M. Givskov, 8 114 
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December 2010, European Patent Application, No. 10194154.0 and US provisional 115 
application, No. 61/420,922). The in vitro experiments showed significant inhibition of a 116 
subclass of QS-regulated P. aeruginosa genes and a significant synergistic action with 117 
tobramycin with respect to the reduction of viability of biofilm cells. Furthermore, a 118 
pulmonary infectious mouse model was employed to demonstrate the antimicrobial effect 119 
of ajoene on P. aeruginosa infections.  120 
 121 
Materials and methods 122 
Bacterial strains 123 
Sequenced P. aeruginosa PAO1 wild-type obtained from the Pseudomonas Genetic Stock 124 
Center (www.pseudomonas.med.ecu.edu, PAO0001). For detection of QSI activity 125 
following reporter strains were used; QSI selector 1 strain (QSIS1, E. coli), lasB-gfp, 126 
rhlA-gfp (P. aeruginosa) and luxI-gfp (E. coli) monitor strains described in (58), (32), 127 
(77) and (4) respectively. Production of AHL’s was detected by using the following 128 
reporter strains; lasB-gfp (E. coli) (32) and ahyI-gfp (E. coli) (30). Animal experiments 129 
were performed with the wild-type P. aeruginosa strain (PAO1) obtained from Professor 130 
Barbara Iglewski (University of Rochester Medical Center, NY, USA). The strain is QS-131 
proficient, except for reduced production of C4-HSL previously noted for this P. 132 
aeruginosa variant (39). The clinical isolate CF438 was obtained from a child with CF 133 
and kindly provided by Helle K. Johansen and Oana Ciofu. The mucoid and non-mucoid 134 
isogenic strains are described in (44, 72). 135 
 136 
Growth media and conditions for in vitro and in vivo experiments 137 
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BT minimal medium (B medium (17) plus 2.5 mg thiamine l-1 and 10% A10 (17)) 138 
supplemented with 0.5% (wt/vol) glucose and 0.5% (wt/vol) Casamino acids were used 139 
for growing the monitor strains (overnight cultures) for the QSI indicator screens. All 140 
strains were incubated at 30ºC with shaking (180 rpm) and supplemented with antibiotics 141 
where appropriate. For animal experiments bacteria from freezer stocks were plated onto 142 
blue agar plates (State Serum Institute, Denmark) and incubated at 37ºC overnight. Blue 143 
agar plates are selective for Gram-negative bacilli (34). One colony was used to inoculate 144 
overnight cultures grown in Luria–Bertani (LB) medium at 37ºC with shaking. 145 
 146 
Extraction and purification of QS containing fractions from garlic 147 
Fractions containing QS activity were identified by a QSIS1 bioassay guided 148 
fractionation according to (58). Garlic cloves were skinned, homogenized in toluene and 149 
stirred overnight with an equal volume of water. The garlic pulp was filtered and the 150 
solvents separated, dried under vacuum and tested for QSI activity. Activity was only 151 
observed from the toluene extract. The extract was fractionated on a C18 column (125g, 152 
200 x 50 mm) on a Biotage® Isolera™ flash purification system (Isolera) with a flow rate 153 
of 30 mL/min with sample added as dry load. Samples were collected (without detection) 154 
as 100 mL fractions, first sample at 10% MeOH in H2O, the following 10 samples were 155 
eluted with a 10-100% MeOH gradient (1000 mL) and all subsequent samples 100% 156 
MeOH (typically 500 mL). Activity was detected in the 50-60% MeOH fractions, which 157 
were combined and further purified by semi preparative HPLC on a Chromolith RP-18e 158 
column (100 x 4.6 mm) with a flow rate of 2 ml per min, eluting with 30% MeCN and 159 
increasing to 37% MeCN over 20 min. A single fraction eluting at 9.5 min was 160 
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determined to have QSI activity. Positive electrospray (ESI+) high-resolution mass 161 
spectrometry (HRMS) gave a mass of 235.0282 Da, corresponding to a formula of 162 
C9H15OS3. Comparison of 1H-NMR data identified this fraction as a 60:40 mixture of E 163 
and Z ajoene (11). 164 
 165 
Chemically synthesized ajoene 166 
Ajoene was synthesized from commercially available distilled allyl disulfide as a 1:4 167 
mixture of E:Z isomers according to (M. Givskov, 8 December 2010, European Patent 168 
Application, No. 10194154.0 and US provisional application, No. 61/420,922). Synthetic 169 
ajoene was purified by silica gel chromatography and characterized by 1H-NMR, 13C-170 
NMR and HRMS. The purity was greater than 98%. Synthetic ajoene was used in all 171 
experiments conducted in this paper. 172 
 173 
Determination of inhibitor strength  174 
The following bioassays were used to determine inhibitor activity of ajoene. ABT 175 
medium (150 µl) supplemented with 0.5% (wt/vol) glucose and 0.5% (wt/vol) Casamino 176 
acids were added to all wells in a 96 wells microtiter dish (Black Isoplate®, Perkin 177 
Elmer). To the first column ajoene is added to a final concentration of 200 µg/ml and a 178 
twofold serial dilution is made. No ajoene was added to the last column, which was used 179 
as a reference. At last, 150 µl overnight cultures of the QSI monitors (lasB-gfp (32), rhlA-180 
gfp (77) or luxI-gfp (4)) were added to all the wells to a final OD450nm on 0.1. 181 
Additionally, the signal molecule OHHL was added to the luxI-gfp reporter screen in a 182 
final concentration of 100 nM. The growth of the bacteria cells (OD450) and the GFP 183 
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expression (excitation wave length, 485 nm and emission wave length, 535 nm) was 184 
measured on a multilabel plate reader Wallac 1420 VICTOR2 (Perkin Elmer) every 15 185 
min over 14 h. The temperature was held constant at 34ºC.  186 
 187 
Production of QS signal molecules 188 
Production of C4-HSL and 3-oxo-C12-HSL was detected in the supernatant from an 189 
overnight culture of clinical isolate (CF438) by using the AHL-specific reporter strains 190 
and the method described by Hentzer et al., (32).   191 
 192 
RNA preparation for DNA microarray analysis 193 
Exponential growing (OD600nm of 0.5) P. aeruginosa PAO1 at 37°C, 180 rpm in AB-194 
media supplemented with 0.5% Casamino acid were diluted to an OD600nm of 0.05. When 195 
reaching OD600nm of 0.5 the culture were divided into 5 cultures of 50 ml and the 196 
following four concentrations of ajoene were added; 10 µg/ml, 20 µg/ml, 40 µg/ml and 197 
80 µg/ml and to one culture no ajoene was added. At OD600nm of 2.0 samples were 198 
retrieved and two volumes of RNAlater (Ambion) were added. Isolation of RNA was 199 
performed using the RNeasy Mini Purification Kit (Qiagen) with on-column DNase 200 
treatment. The following synthesis of cDNA and hybridization were performed by the 201 
microarray core-unit at Rigshospitalet, Denmark. The gene expressions were analyzed by 202 
the use of the software ArrayStar v3.0 (DNAstar). DNA microarray analysis of global 203 
gene expression was performed according to guidelines provided by Affymetrix and 204 
repeated three times with RNA from three individual growth experiments.  205 
 206 
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Real Time PCR 207 
The purified RNA used for DNA microarray was also used for RT-PCR. cDNA was 208 
made from 1 μg of RNA using the High Capacity RNA-to-cDNA Master Mix (Applied 209 
Biosystems). For quantitative real-time PCR, amplification was performed with Power 210 
SYBR Green Master Mix in a Step One Plus Thermal Cycler (Applied Biosystems). The 211 
primers were designed using Primer Express3.0 (Applied Biosystems). Forty cycles were 212 
run with denaturation at 95°C for 15 seconds, annealing at 55°C for 30 seconds, and 213 
extension at 60°C for 45 seconds. The gene rpoD was used as control for standardization. 214 
Primer sequences: rhlA forward; 5’-GGCGATCGGCCATCT-3’, rhlA reverse; 5’-215 
AGCGAAGCCATGTGCTGAT-3’, lasB forward; 5’-CGACAACGCGTCGCAGTA-3’, 216 
lasB reverse; 5’-AGGTAGAACGCACGGTTGTACA-3’.  rpoD forward; 5’-217 
ACAAGATCCGCAAGGTACTGAAG-3’, rpoD reverse; 5’-CGCCCAGGTGCGAATC-218 
3’. 219 
 220 
Measurements of total rhamnolipid production 221 
Samples for measurements of total rhamnolipid concentration were retrieved from the 222 
cultures grown for DNA-microarray and RT-PCR at OD600nm of 1.5 and 2.0 and kept at -223 
80°C until further examinations. HPLC with ESI+-HRMS detection (47) was used to 224 
quantify rhamnolipids as their [M+NH4]+ (peak area) based on external standard 225 
quantification of a NMR validated rhamnolipid B standard. A series of diluted standard 226 
was analyzed before and after the samples, in order to minimize potential differences in 227 
ionization levels of rhamnolipid between the samples. Other rhamnolipids were assumed 228 
to give the same ionization efficiency as rhamnolipid B. Total rhamnolipid concentration 229 
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was derived from the six major rhamnolipids, with the following masses [M+NH4]+: 230 
668.4 (rhamnolipid B, C10-C10-rha-rha), 694.4 (C10-C12D-rha-rha), 696.4 (C10-C12-231 
rha-rha), 522.4 (C10-C10-rha), 548.4 (C10-C12D-rha); and 550.4 (C10-C12-rha). 232 
 233 
Stability of ajoene 234 
Overnight cultures of the following strains; P. aeruginosa PAO1, ∆lasR-∆rhlR and ∆lasI-235 
∆rhlI were diluted to OD600nm of 0.2 and incubated with 100 µg/ml ajoene at 37°C and 236 
4°C for 18 h. The samples were sterile filtrated (0.22 µm pore size) and to measure QSI 237 
activity of ajoene the supernatant were tested in the P. aeruginosa QSI screen using the 238 
lasB-gfp monitor strain (see “Determination of inhibitor strength”).   239 
 240 
Effect of ajoene on P. aeruginosa QS signal molecule content 241 
Production of AHL was quantified by HPLC with tandem mass spectrometry (MS/MS) 242 
as described in (60). P. aeruginosa was grown as for DNA-array and RT-PCR with the 243 
same concentrations of ajoene added. At OD600nm of 1.5, 1.8 and 2.0, samples were 244 
retrieved and sterile filtrated (0.22 µm pore size). Acidified ethyl acetate was added to the 245 
supernatant in a 1:1 ratio and left at room temperature over night. The top phase was 246 
withdrawn and concentrated under nitrogen gas and resuspended in 500 µl EtOH, with 1 247 
µl analysed by HPLC-MS/MS (60). In this case external standard quantification was 248 
done. The method detects C4-HSL, open lactone-C4-HSL, 3-oxo-C12-HSL, and open 249 
lactone-3-oxo-C12-HSL. Detection limits were in the 10–30 nM range. 250 
 251 
Effect of serum albumin on the QSI activity of ajoene 252 
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The P. aeruginosa QSI screen (lasB-gfp) was used to test the effect of serum albumin on 253 
ajoene activity. Bovine serum albumin was dissolved in the ABT-media to a 254 
concentration of 100 mg/ml. 300 µl were added to the first row of a 96 wells microtiter 255 
dish (Black Isoplate®, Perkin Elmer). To the rest of the rows 150 µl media without serum 256 
albumin were added. A 2 fold serial dilution of serum albumin was made and ajoene 257 
added to the following final concentrations; 12.5 µg/ml and 25 µg/ml. Finally 150 µl of 258 
the lasB-gfp monitor strain were added to all the wells (for a more detailed description 259 
see “Determination of inhibitor strength”).   260 
 261 
In vitro biofilms 262 
Biofilms were grown at 37ºC in continuous-culture, once-through, three channel, flow 263 
cells with individual channel dimensions of 1*4*40mm perfused with sterile AB trace 264 
minimal medium containing 0.3 mM glucose as described by Christensen et al. (15) and 265 
Pamp and Tolker-Nielsen (49). Overnight cultures were diluted to 0.1 at OD600nm in 0.9% 266 
NaCl, and 250 μl was used for inoculation per channel. All microscopic observations and 267 
image acquisitions were performed using a confocal laser scanning microscope (Leica 268 
TCS SP5, Leica Microsystems, Germany). Images were obtained with an x40/dry 269 
objective and x100/oil objective. To visualize dead bacterial cells and lysed PMNs, 270 
propidium iodide (PI) (P-4170; Sigma) was used, whereas expression of GFP was used as 271 
a measure for live bacterial cells. Image scanning was carried out at 488 nm (green) and 272 
543 nm (red) laser line from an Ar/Kr laser. Imaris software package (Bitplane AG) was 273 
used to generate pictures of the biofilm. Tobramycin was diluted in 0.9% NaCl. The 274 
medium containing ajoene was kept on ice during the experiment. 275 
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 276 
Preparation of PMNs 277 
Isolation of PMNs was performed according to Bjarnsholt et al. (6) with modifications. 278 
Human blood was collected from normal healthy volunteers in BD Vacutainers 279 
containing 0.129 M sodium citrate. PMNs were resuspended in RPMI 1640 with 280 
NaHCO3 to obtain a concentration of 1.5*107 PMNs/ml.  281 
 282 
PMN exposure of biofilms 283 
The exposure experiment was performed as described by Bjarnsholt et al. (6). We 284 
evaluated the biofilm and PMN interactions every 30 min for 2 hours. Necrotic PMNs 285 
were demonstrated as increased red fluorescence from the supplemented DNA stain PI.  286 
 287 
Animals 288 
Female BALB/c mice were purchased from Taconic M&B A/S (Ry, Denmark) at 9-11 289 
weeks of age and were maintained on standard mouse chow and water ad libitum for a 290 
minimum period of 1 week before the challenge.  291 
The animal studies were carried out in accordance with the European convention and 292 
directive for the Protection of Vertebrate Animals used for Experimental and Other 293 
Scientific Purposes and the Danish law on animal experimentation. All experiments were 294 
authorized and approved by the National Animal Ethics Committee, Denmark (The 295 
Animal Experiments Inspectorate, dyreforsoegstilsynet.dk), and given the permit number 296 
2008/561-1466. All surgery was performed using hypnorm/midazolan and pentobarbital 297 
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was used to euthanize the mice at the termination of the experiments. All efforts were 298 
made to minimize suffering. 299 
 300 
Pulmonary infection model 301 
The pulmonary infection model in mice was prepared and performed according to (10). 302 
The ajoene solution used for the treatment group was prepared as follows: ajoene was 303 
dissolved in 96% ethanol to a concentration of 100 mg/ml and diluted 40x in a 20% 304 
vehicle solution ((2-hydroxypropyl)-β-cyclodextrin (Sigma, cat. no. C0926) dissolved in 305 
0.9% NaCl) to a concentration of 2.5 mg/ml reducing the concentration of ethanol to 306 
2.4%. Each mouse were treated with 25 mg ajoene kg-1 BW subcutaneously (s.c.) once a 307 
day as prophylactic treatment for two days, right after infection and subsequently two 308 
days post-infection. The placebo group received 96% ethanol diluted in the vehicle 309 
corresponding to the amount of ethanol that the ajoene treated group received. 310 
 311 
Statistical Analysis 312 
The number of mice in each group was calculated to provide a power of 0.8 or higher for 313 
continuous data. For analysing quantitative data the Mann-Whitney U test was used for 314 
calculating p-values in the statistical program GraphPad Prism (GraphPad software, Inc., 315 
San Diego, USA, version 5.0). P-values ≤ 0.05 were considered significant. 316 
 317 
Apoptosis assay 318 
Apoptosis tests in the lung epithelial cell line A549 (purchased from the German 319 
Collection of Microorganisms and Cell Lines DMSZ, Braunschweig, Germany) was 320 
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performed by flow cytometry using a fluorescein isothiocyanate [FITC]-conjugated 321 
antibody to cleaved Poly [ADP –ribose] polymerase (PARP) (Cell Signaling Technology, 322 
Denver, CO, USA). Samples of 5 × 105 cells were incubated in the presence of various 323 
concentrations of ajoene in six-well plates for 4 h. Subsequently, cells were detached with 324 
trypsin/EDTA, washed twice and fixed in 2% formaldehyde for 15 min, permeabilized by 325 
0.1% Saponin (Roth GmbH, Karlsruhe, Germany) in PBS for 60 min and incubated with 326 
anti-cleaved-PARP according to the manufacturer's protocol for 30 min. For positive 327 
control, cells were cultured in the presence of apoptosis inducer tetrandrine (Sigma 328 
Aldrich, Steinheim, Germany) for 4 h (12). 329 
 330 
Proliferation assay 331 
Interference of ajoene with A549 cell proliferation was measured employing an MTS 332 
proliferation assays (Promega, Mannheim, Germany) following the manufacturer’s 333 
protocol.  334 
 335 
Toxicity assay 336 
Cytotoxicity testing was performed using a lactate dehydrogenase release based assay kit 337 
purchased from Roche Applied Science (Mannheim). A549 lung epithelial cells were 338 
exposed to concentration series of test substances for 24 h before LDH release was 339 
determined according to the manufacturer’s instructions. 340 
 341 
Results 342 
Ajoene is the major bioactive QSI compound in garlic extract  343 
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Previously demonstrations of inhibition of QS in P. aeruginosa with crude and partially 344 
purified garlic extracts (8) encouraged us to further identify and assess the efficacy of the 345 
pure QS inhibitor. In our hands, Spanish garlic appeared to contain a higher level of 346 
bioactivity with respect to QS inhibition, compared to those obtained from other countries 347 
including China and Argentina (data not shown). The compounds present in garlic bulb 348 
extracts were stable to time, protease activity and various evaporation techniques at room 349 
temperatures, and it was only at high temperatures that degradation was observed. An 350 
iterative process of fractionation and assaying was applied to crude garlic extracts to 351 
determine the presence of any potential QSI compounds (bioassay-guided fractionation). 352 
Several different water extracts were investigated, initially testing several different 353 
columns for fractionation and purification. These columns included matrices consisting of 354 
C18, Sephadex G10 and LH20, and HILIC (hydrophilic interaction chromatography), 355 
however, in the end ajoene was isolated on C18 material, as described in the materials and 356 
methods section. During examination of the initial water extract, the activity was lost. 357 
Investigations showed that the active compound was most likely degraded or adsorbed to 358 
sodium sulfate (used as a drying agent). Consequently, the focus was switched to the 359 
toluene phase. The toluene extracts continuously showed a high level of QSI activity. The 360 
treatment of these extracts was similar to that of the water extracts, however all drying 361 
agents were avoided in case of absorption of the active compounds. In this case the 362 
primary column matrixes used were DIOL, Silica gel (Si) and C18. Bioassay-guided 363 
fractionation based on Quorum Sensing Inhibition Screens (QSI Screens: QSIS1, lasB-364 
gfp and rhlA-gfp) of these extracts isolated a single primary compound responsible for the 365 
in vitro activity. This compound was isolated and examined with Mass Spectrometry 366 
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(MS) and Nuclear Magnetic Resonance (NMR) (data not shown) and identified as ajoene 367 
(Fig. 1). In addition several ajoene derivatives (Fig. 1) were shown to be present. Ajoene 368 
is a lipid-soluble allyl sulfide formed from allicin which is converted from alliin by an 369 
enzymatic process when garlic is crushed (11). A range of different organosulfur 370 
compounds are formed in this process with ajoene being among of the most abundant 371 
(37). To further investigate the QSI bioactivity, we used chemically synthesized ajoene 372 
prepared by a recently published method (M. Givskov, 8 December 2010, European 373 
Patent Application, No. 10194154.0 and US provisional application, No. 61/420,922). 374 
Both naturally occurring and chemically synthesized ajoene exist as two isomers, (Z) and 375 
(E), in different ratios dependent on the preparation method (Fig. 1).   376 
 377 
To determine the QSI activity of ajoene, dose-response curves were created using two 378 
QSI reporter systems which contain fusions of the QS controlled lasB promoter and rhlA 379 
promoter to gfp(ASV) encoding an unstable GFP variant in a P. aeruginosa background 380 
(32, 77). We also used a QS reporter system harbored in an E. coli background where the 381 
luxR gene and the promoter region of the luxI is fused to gfp(ASV) (4). In all three 382 
reporter systems, induction of the QS system can be measured as increasing fluorescence. 383 
The presence of an antagonist decreases GFP expression and thus fluorescence is 384 
proportional to the concentration or effectiveness of the QSI present. Growth of the 385 
reporter strains was monitored to make sure that the concentrations of added ajoene were 386 
not affecting primary metabolic functions and thereby altering growth rate. IC50 values 387 
were calculated from the curves expressing the specific fluorescence (Gfp expression/cell 388 
density) (Fig. 2), giving the following values: lasB-gfp, 15 μM; rhlA-gfp, 50 μM and luxI-389 
gfp, 100 μM. The calculations were performed by plotting the maximal slopes from the 390 
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curves obtained with the different reporter strains as a function of the concentrations of 391 
ajoene. The slope represents the synthesis rate (ΔRFU/OD450/Δtime). 392 
 393 
Target gene specificity 394 
DNA microarray analysis was used to identify the target gene specificity of ajoene. As a 395 
reference we have used the QS regulon previously identified by Hentzer et al. (33). In the 396 
past this dataset has been used to validate target specificity of putative QSI compounds. 397 
The study by Hentzer et al. (33) defines QS regulated genes as those genes for which the 398 
expression is altered more than 5-fold in a ΔlasI-ΔrhlI mutant in response to the addition 399 
of exogenous C4-HSL and 3-oxo-C12-HSL. Genes with less than 5-fold alteration in 400 
expression between treated and non-treated cultures were not included in this study. 401 
Exponentially growing P. aeruginosa cultures were treated with the following four 402 
concentrations of ajoene: 10 µg/ml (42.7 µM), 20 µg/ml (85.4 µM), 40 µg/ml (170.8 µM) 403 
and 80 µg/ml (341.6 µM), none of which affect growth (see supplemental material, Fig. 404 
S1). The samples were retrieved at an OD600nm of 2.0 (optical density) as previous 405 
investigations have shown the highest activity among the QS genes at this particular cell 406 
density.  407 
Only a small number of genes were significantly (p<0.05) more than 5-fold down-408 
regulated by the four different concentrations of ajoene; 0 (10 µg/ml), 0 (20 µg/ml), 2 (40 409 
µg/ml) and 11 (80 µg/ml). According to the QS regulon defined by Hentzer et al., 10 of 410 
the 11 genes and according to Rasmussen et al. (59), all the genes down regulated more 411 
than 5-fold by ajoene are defined as QS regulated. There is a clear relationship between 412 
an increasing concentration of ajoene used for treatment and the degree of regulation of 413 
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the target genes. The transcriptomic analysis indicated that the optimum concentration for 414 
repression of the target genes is close to 80 µg/ml ajoene. Attempts to repress more than 415 
those 11 genes (out of a total of 5570 P. aeruginosa genes) were not possible without 416 
supplementing cultures with concentrations that would also affect growth. This means 417 
that ajoene administered at this optimum concentration exhibits a high degree of target 418 
specificity towards a small subgroup of the QS regulon. Five genes were significantly 419 
(p<0.05) more than 5-fold up regulated in response to treatment with 80 µg/ml ajoene and 420 
with the three lower ajoene concentrations there were only a few genes for which 421 
expression was significantly altered. Three of the genes are encoding components of a 422 
type VI secretion system (tagQ1, PA0070; tssB1, PA0083; hcp1, PA0085), and the other 423 
two genes are (exaC, PA1984) and (PA0182) which is a probable short-chain 424 
dehydrogenase. Among the genes significantly down-regulated by ajoene were the 425 
following QS regulated important virulence factors, LasA protease (lasA, PA1871), 426 
chitinase (chiC, PA2300), the cytotoxic galactophilic lectin (lecA, PA2570), the 427 
rhamnosyl transferase AB operon (rhlA, PA3478 and rhlB, PA3479), the PvdS-regulated 428 
endoprotease (prpL, PA4175) that degrades casein, elastin, lactoferrin, transferrin, and 429 
decorin (75), and the associated chitin-binding protein cbpD (PA0852) which mediates 430 
attachment to chitin-containing substrates and presumably assist in biofilm formation 431 
(26) (Table 1). None of the treatments seemed to affect transcription of the genes 432 
encoding central regulatory genes of the QS circuit. This is similar to other previously 433 
published QSI compounds including furanone C-30 (33), patulin and penicillic acid (59), 434 
and indicates that interaction of the inhibitor with its target may occur at the post-435 
transcriptional level. 436 
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 437 
To verify the microarray data, RT-PCR was performed with the two stringently QS-438 
regulated genes lasB and rhlA (Fig. 3). When comparing the two experimental methods, 439 
repression of the two genes followed the same trend, with a slightly stronger reduction 440 
observed with the RT-PCR based method. The RT-PCR data showed that a concentration 441 
of 80 µg/ml ajoene lowered expression of rhlA almost 12-fold and lasB almost 5-fold. 442 
According to Rasmussen et al. (59), the genes listed in table 1 are (except for prpL which 443 
is exclusively regulated by the Las QS system) subject to regulation by both the Las and 444 
Rhl QS systems. This suggests that ajoene may primarily target the Rhl system.  445 
 446 
Attenuation of rhamnolipid production by ajoene  447 
To exemplify the actual efficacy of ajoene in down regulating one of the important 448 
virulence factors, the concentration of rhamnolipid present in the cultures grown for DNA 449 
array and RT-PCR were directly quantified by LC-MS. The production of rhamnolipids 450 
encoded by the rhlA, rhlB and rhlC genes (PA3479, PA3478 and PA1131) is initiated in 451 
early stationary phase and coordinately regulated by the Rhl and the PQS systems (57, 452 
73). Samples where therefore retrieved at an OD600nm of 1.5 and 2.0 to monitor 453 
rhamnolipid production before and after the synthesis was fully induced. The data 454 
showed clearly that there was an increase in rhamnolipid production from an OD600nm 455 
from 1.5 to 2.0. The concentrations of rhamnolipid in the samples correlated inversely 456 
with increasing concentrations of ajoene. When treated with 20 µg/ml ajoene at an 457 
OD600nm of 2.0, the rhamnolipid content were reduced to approximately 1/3 compared to 458 
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the untreated culture and there was almost no detectable rhamnolipid present in the 459 
sample when the cells were treated with 80 µg/ml ajoene (Fig. 4).  460 
 461 
Effect of ajoene on P. aeruginosa QS signal molecule production 462 
According to the transcriptomic analysis the genes inhibited by ajoene treatment could 463 
indicate a posttranscriptional effect on gene products responsible for generation of C4-464 
HSL. To test this, the concentrations of C4-HSL and 3-oxo-C12-HSL in untreated and 465 
ajoene-treated cultures were determined by HPLC-MS/MS at three different cell densities 466 
(OD600nm at 1.5, 1.8 and 2.0). The concentration of C4-HSL was found to inversely 467 
correlate with increasing concentration of ajoene and at a concentration of 80 µg/ml of 468 
ajoene the level was reduced almost 3-fold compared to the untreated control. With 469 
respect to the concentration of 3-oxo-C12-HSL, there was no consistent effect with 470 
increasing concentrations of ajoene (Fig. 5).   471 
 472 
Ajoene treatment renders in vitro biofilms rhamnolipid deficient and thereby 473 
prevents the killing of PMNs 474 
The effect of ajoene on rhamnolipid production prompted us to investigate whether this 475 
would in fact inhibit lysis of PMNs. P. aeruginosa biofilms were grown for four days 476 
either in the presence or absence of 100 μg/ml ajoene.  When freshly isolated PMNs were 477 
subsequently introduced into the flow chambers of the biofilms grown in the absence of 478 
ajoene, propidium iodide staining (PI) indicated extensive necrosis of the PMNs (Fig. 479 
6A). In contrast, when the biofilm were grown in the presence of ajoene prior to PMN 480 
exposure, no necrosis of the PMNs was observed (Fig. 6B). 481 
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 482 
Ajoene enhanced tobramycin effect on P. aeruginosa biofilm  483 
We have previously published an in vitro treatment study of biofilms grown in the 484 
presence of QSI bioactivities including those associated with garlic extract and furanone 485 
C-30 where QS inhibition was found to greatly enhance the antimicrobial effect of 486 
tobramycin (8, 33). Biofilms of P. aeruginosa strain were grown either in the presence or 487 
absence of 100 µg/ml ajoene. At day three the biofilms were treated with 10 µg/ml 488 
tobramycin for 24 h. A pilot study on biofilms grown in the absence of ajoene indicated 489 
that treatment with 10 µg/ml, 100 µg/ml nor 340 µg/ml tobramycin showed no difference 490 
in the extent of killing as judged from live dead staining and inspection by means of 491 
confocal scanning laser microscopy. Our analysis showed a more than 90% killing of 492 
cells when the biofilms were grown in the presence of ajoene and subsequently treated 493 
with 10 µg/ml tobramycin (Fig. 7A). The synergistic effect was also evaluated on the 494 
clinical CF isolate CF438 (a first isolate from a diagnosed CF child), which possesses 495 
functional QS systems and once again extensive killing of the biofilm was recorded (Fig. 496 
7B).  497 
 498 
Antimicrobial effects in vivo 499 
We performed three individual in vivo treatment experiments with ajoene in a pulmonary 500 
infection model in mice using 25 µg ajoene g-1 BW. When combining the experiments a 501 
significant difference on day three was seen (p<0.002) with a more than 500-fold 502 
difference recorded in clearance between the groups (Fig. 8). Experiments with a lasR 503 
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rhlR double mutant showed that this is the maximum obtainable difference in clearance 504 
that can be obtained in this infection model (6).  505 
 506 
Treatment of mice infected with clinical CF isolates 507 
In CF patients, the appearance of the mucoid phenotype is considered a clinical marker 508 
for the onset of the chronic infection, which correlates with a poor prognosis for the 509 
infected CF patients. To test the efficacy of ajoene treatment on a QS proficient mucoid 510 
P. aeruginosa strain, we adopted a clinical isolate from a patient who had a chronic 511 
infection with P. aeruginosa for 16 years (44, 72). After administration of 25 µg/g ajoene 512 
we noted an induction of abscesses, which resulted in an increase in the bacterial load in 513 
the lungs. This phenomenon was not observed with the placebo group. The experiment 514 
was performed twice with similar results. We then repeated the experiment with 12.5 515 
µg/g and 6.25 µg/g ajoene treatments. The concentration of 12.5 µg/g gave the best 516 
results with respect to bacterial clearance and apparent wellbeing of the mice, but the 517 
clearance in the treatment group was not significantly different from the placebo group 518 
(p<0.5). Treatment with 6.25 µg/g of ajoene did not have any significant effect on 519 
clearance when compared with the placebo group (data not shown). An isogenic, 520 
nonmucoid derivative of the clinical isolate was also investigated in a treatment study 521 
using 12.5 µg/g of ajoene. This isolate cleared very rapidly from the lungs of the mice. 522 
Therefore the experiment was evaluated at day one after infection. The difference 523 
between the treated group and the placebo group showed a non-significant (p<0.1) two 524 
orders of magnitude reduction (data not shown). Both isolates have a functional QS 525 
system (44). To investigate the efficacy of ajoene on an early clinical P. aeruginosa 526 
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isolate, an experiment with the first isolate of P. aeruginosa from a CF patient was 527 
conducted by treating the infected mice with 12.5 µg/g of ajoene. The experiment was 528 
evaluated at day one since the strain is highly virulent and therefore the mice would not 529 
survive for a three-day period. There was a significant difference (p<0.05) between the 530 
treated group and the placebo group and a 20-fold difference (data not shown). The 531 
isolate were tested positive for functional QS system (data not shown).  532 
 533 
Stability of ajoene under experimental conditions  534 
To test the stability in the presence of bacteria and whether ajoene could interact directly 535 
with the QS signal molecules, 50 µg/ml of ajoene was incubated over night at 37°C and 536 
4°C with P. aeruginosa (PAO1), QS-deficient ∆lasI rhlI, ∆lasR rhlR mutant, pure C4-537 
HSL, pure 3-oxo-C12-HSL and a sample with no additions. Following the incubations, 538 
ajoene activity in the supernatant was assessed by means of a lasB-gfp dose-response 539 
bioassay. The activity in the supernatant disappeared after incubation with bacteria at 540 
37ºC overnight whereas there was no decrease in ajoene activity when incubated with 541 
bacteria at 4ºC or incubated in the absence of bacteria at 4ºC and 37ºC. There was no 542 
change in ajoene activity when incubated with pure C4-HSL and 3-oxo-C12-HSL, which 543 
indicates that ajoene is not likely to chemically react with the signal molecules and cause 544 
their inactivation (data not showed).  545 
 546 
Effect of BSA on the bioactivity of ajoene 547 
Because of putative annihilating effects of serum proteins on the bioactivity of ajoene, 548 
concentrations ranging from 12.5 µg/ml to 50 µg/ml of ajoene were incubated with 549 
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bovine serum albumin (BSA). There was no notable reduction in the QSI activity of 550 
ajoene in the range of concentrations tested with serum albumin in concentrations up to 551 
50 mg/ml, i.e. the concentration, which corresponds to the content in adult serum (see 552 
Supplemental material, Fig. S2).    553 
 554 
Effects of ajoene on human lung epithelial cells 555 
A549 human lung epithelial cells were employed as a model system to quantify potential 556 
apoptosis-inducing effects. According to cytometric determination of cleaved PARP as a 557 
marker, ajoene promotes apoptosis with an EC50 in the range of 100 μM (23 μg/ml). The 558 
PARP-activating effect of ajoene on lung epithelial cells was about tenfold weaker than 559 
that of positive control tetrandrine, a natural compound used in Chinese medicine for the 560 
treatment of lung disorders such as silicosis (12). Consistent with these findings, ajoene 561 
inhibited proliferation of A549 cells with an IC50 in the range of 100 μM and is about one 562 
order of magnitude less potent in impairment of proliferation than the control compound 563 
tetrandrine. General cytotoxicity in terms of induced cytolysis was determined by the 564 
release of lactate dehydrogenase (LDH), and, hence, LDH activity, from damaged A549 565 
cells. Ajoene induced LDH release in a dose-dependent manner with an EC50 of 200 μM. 566 
It was found approximately tenfold less cytotoxic than the established furanone QS 567 
inhibitor compound C-30 (see supplemental material, Fig. S3A-D). Taken together, 568 
results from three independent assays coherently characterize ajoene as a compound with 569 
relatively weak interference with cell physiology of the lung epithelium. 570 
 571 
Discussion 572 
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Intriguingly, worldwide emerging problems of infection control parallels a marked 573 
slowdown in the development of new antibiotics. Many pharmaceutical companies no 574 
longer have antibiotic drugs in the pipeline or research activities in the field. There are 575 
both strategic and economic reasons for this, but there have been profound scientific 576 
difficulties for the pharmaceutical industry in this context. One major limiting factor is 577 
that the study of free-living, planktonic bacteria has provided the basis for our general 578 
understanding of microbial life and in particular infectious diseases. Consequently, in the 579 
traditional design of antibiotic drugs, it is not appreciated that the biofilm habitat may 580 
dominate in chronic infections just as it does in the environment. Antimicrobial treatment 581 
of biofilms is a challenge, in particular when it comes to heterogeneity, which is likely 582 
one of the special features that provide biofilm bacteria such remarkable resilience.  583 
The archetypical biofilm disease has for a long time been considered to be the P. 584 
aeruginosa infection in CF patients. Furthermore, a recent investigation by us pointed out 585 
that the early colonizers of CF children have functional QS systems. The first system lost 586 
is the Las but the strains are still able to express rhamnolipid and other PQS and C4-HSL 587 
controlled genes (7). Therefore, strategies that help in disabling the protective 588 
mechanisms of P. aeruginosa, in particular the rhamnolipid shield and eDNA production, 589 
are likely to be employed as a worthwhile addition to conventional antimicrobial 590 
chemotherapy. Different approaches can be used to identify and harness the QS inhibitors 591 
obtained from natural sources. Extraction of natural products has provided several 592 
positive QSI molecules among them the Delisea pulchra furanones (32) and patulin from 593 
Penicillium coprobium (59). It is interesting that sulfur-containing compounds appear as 594 
a new class of molecules capable of inhibiting QS (3, 5). Li et al. (40), found two sulfur 595 
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containing compounds from an in silico based virtual screening to target the AI-2 QS 596 
system from Vibrio harveyi and several analogues were identified to exert bioactivity 597 
(52). These molecules contain a sulfone group in contrast to ajoene, which contains 598 
disulfide and sulfinyl groups. For a more detailed description of identified QSIs please 599 
see Galloway et al. (29). 600 
We have shown that approximately 80 μg/mL (341,6 µM) ajoene efficiently switches off 601 
the expression of the rhlA-gfp fusion in our dose-response bioassays and down regulates 602 
the rhlA gene expression extensively which corresponds to the decrease in concentration 603 
of rhamnolipid directly measured by HPLC. The gene rhlA encodes a 604 
rhamnosyltransferase, which catalyses a glycosyl transfer reaction in rhamnolipid 605 
synthesis. Rhamnolipids are glycolipids that have strong surfactant abilities. One 606 
rhamnolipid in particular, rhamnolipid B, is one of the two more abundant rhamnolipids 607 
and has been shown to cause necrosis of PMNs (36). Previously published data with a 608 
ΔrhlA mutant (71) (which is only defective in rhamnolipid synthesis) make us strongly 609 
believe that rhamnolipid is responsible for the lytic killing of the PMNs, also in vivo. We 610 
have shown that ajoene treatment of in vitro biofilms prevents the killing of PMNs. These 611 
experiments furthermore suggest that ajoene treatment is capable of attenuating the 612 
production of rhamnolipids. In addition, ajoene treatment is capable of rescuing the 613 
PMNs and likely to restore the action of the PMNs. The same results were observed with 614 
a ΔrhlA mutant (71) – almost no necrotic PMNs were detected when exposed to biofilms 615 
of the rhamnolipid-deficient mutant.  616 
One important issue in the treatment of bacterial biofilm infections is the lowered 617 
effectiveness of administered antibiotics. An infection in the airways of CF patients will 618 
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result in high concentrations of anionic polyelectrolytes like DNA (14) released from 619 
lysed inflammatory cells such as the PMNs and bacteria. It has been shown that anionic 620 
polyelectrolytes, in particular DNA, bind to and reduce the activity of cationic antibiotics 621 
like tobramycin (74, 78) which can lead to a decrease in the biological availability of 622 
tobramycin to as low as 5% of the existing dose (43). This suggests that by blocking the 623 
production of eDNA it is possible to attenuate the otherwise subsequent inactivation of 624 
tobramycin. We have shown in vitro that addition of 100 μg/ml ajoene to a biofilm 625 
followed by addition of 10 μg/ml tobramycin kills more than 90% of the biofilm bacteria 626 
whereas the presence of only tobramycin or ajoene had no effect. It is documented that 627 
the release of bacterial eDNA is controlled by QS (2) which, taking into consideration 628 
and combined with our results, points to a possible attenuation of the release of eDNA by 629 
ajoene. This synergistic effect is also relevant in vivo. It has been demonstrated that 630 
treatment of an in vivo P. aeruginosa foreign-body biofilm infection with a combination 631 
of a QSI and tobramycin likewise showed a synergistic clearing effect on the bacteria 632 
(16). The results could be obtained with the use of either of the QSIs: Furanone C-30, 633 
ajoene or horseradish juice extract. In addition, rhamnolipid mediated lysis of attacking 634 
PMNs may significantly contribute to the tobramycin annihilating effects in vivo. Our 635 
data indicate that this chain of neutralizing events may be obstructed by treatment with 636 
QSIs including ajoene.  A recent study showed similar promising results with a treatment 637 
of a Burkholderia cenocepacia infection with a combination of tobramycin and the QSI 638 
baicalin hydrate in a mouse pulmonary model of infection (13). Several published papers 639 
by our group have demonstrated that QS-deficiency (either by mutation or by QSI 640 
treatments) leads to faster clearing compared to bacteria with functional QS in a 641 
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pulmonary infectious mouse model (6, 8, 33). In this study ajoene was administered 642 
prophylactically and continued after infection. Enumeration by plate counts showed a 643 
significant difference between the treated group and the control group on day three. This 644 
is concordant with the results obtained by Bjarnsholt et al. (8), in which raw garlic extract 645 
was used as treatment. In addition, a study by Harjai et al. (31), where garlic extract was 646 
given to mice orally, showed significantly reduced renal bacterial content of P. 647 
aeruginosa at day 5 post infection.  648 
Three different clinical isolates were tested in the lung model to demonstrate the efficacy 649 
of ajoene towards different isolates retrieved from CF patients. Ajoene treatment of a QS-650 
proficient mucoid strain obtained from a CF patient chronically infected for 16 years and 651 
the isogenic nonmucoid strain did not have any significant effect when compared to the 652 
placebo group whereas an ajoene treatment of a first CF isolate showed a significant 653 
difference. This increased susceptibility of the early clinical isolate to the QSI induced by 654 
ajoene is in line with our demonstration of the predominance of intact QS in early isolates 655 
from CF patients (7). These data were obtained after one day post infection because of 656 
difficulties in keeping the mice in a proper healthy condition. Furthermore, were the 657 
ajoene concentration lowered two-fold compared to the studies with wild type. These 658 
modifications (which were taken to comply with ethical constraints) in the experimental 659 
procedure might be the reason for the lower effectiveness of ajoene we obtained with the 660 
clinical strains compared to wild type. When comparing the present studies with ajoene to 661 
earlier studies with garlic extracts, the present study offers a convincing indication of 662 
ajoene being the major active component in garlic able to reduce a P. aeruginosa 663 
infection. Two other sulfur containing molecules previously isolated by us from garlic 664 
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were found to posses QS-inhibitory activity towards the V. fisheri LuxR QS system, but 665 
not against the P. aeruginosa QS systems (53).  666 
The question is whether it would be possible to obtain the promising treatment results in 667 
clinical trials performed on patients suffering from P. aeruginosa infections. The ajoene 668 
content in garlic is found in concentrations up to 172 µg/g of (E)-ajoene and 476 µg/g of 669 
(Z)-ajoene as judged from rice oil heated (80°C) freshly prepared garlic extracts (46). To 670 
match this relatively low herbal content of ajoene with the dosages required for the 671 
present animal treatments, it would require individuals to intake approximately 5 kg of 672 
raw garlic per day. Despite this, a recently published pilot study investigating the effect 673 
of garlic capsules orally administered to CF patients reported a non-significant, but never 674 
the less reduced decline in lung function (FEV1) in the treated group compared with the 675 
corresponding placebo group (65). The exact amount of ajoene present in the capsules 676 
was not determined. However, water extracts made directly on the content of the capsules 677 
showed bioactivity directed against our lasB-gfp reporter (not shown). It remains 678 
therefore unknown if ajoene was present in biologically relevant amounts or whether the 679 
capsules contained ajoene-enhancing components that would increase the effects of low 680 
amounts of ajoene. In fact, we found that synthesized ajoene upon subsequent 681 
purification close to 100% purity as determined by LC-DAD-MS actually lost activity in 682 
the in vivo infectious models (data not shown). For example, fresh garlic extract shows a 683 
much more pronounced effect on the transcriptome of P. aeruginosa compared with 684 
synthesized ajoene (58). In contrast to our garlic extracts previously used, our 685 
transcriptome analysis revealed that synthetic ajoene only affected a few but nevertheless 686 
important QS controlled genes including lasA, chiC and rhlAB, whereas lasB was not 687 
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more than 5-fold down regulated. The effect on primarily QS-controlled genes and the 688 
small amount of genes affected, suggests that synthetic ajoene, in contrast to our previous 689 
garlic extracts, only inhibits expression of a minor part of the QS regulon. In comparison, 690 
with more than 80% of the QS controlled genes down-regulated by furanone C-30 691 
treatment and no effect on signal generation, it is unlikely that ajoene targets both LasR 692 
and RhlR. Sonnleitner et al. (66), have investigated the influence of the SM-like RNA-693 
binding protein Hfq on the QS system. They documented a decrease in elastase, catalase 694 
and pyocyanin production in an hfq knock out mutant (66) and confirmed by 695 
transcriptome analysis that the effect on this subset of QS regulated virulence factors was 696 
mediated by a reduced expression of the corresponding genes (67). The authors suggested 697 
the following interactive path of Hfq and the QS system: Hfq binds to and stabilizes the 698 
regulatory RNA RsmY, which subsequently binds to the RsmA protein, which, in turn, 699 
negatively regulates RhlI messenger translation. Furthermore, they showed a decrease in 700 
the concentration of C4-HSL in both a PAO1rsmY- and a PAO1hfq- strain compared to 701 
the wild type (67), which corresponds to our investigations where the amount of C4-HSL 702 
in cultures decrease with increasing ajoene concentrations. Furthermore, when comparing 703 
our transcriptome analysis with the transcriptome analysis of the PAO1hfq- strain, there is 704 
a compelling correlation with genes, which are significantly down regulated by ajoene 705 
treatment. It is however not trivial to compare the two studies. For example, PAO1hfq- 706 
showed a reduced growth rate compared to the wild type (66). Furthermore, the authors 707 
grew their samples in LB medium and isolated RNA from cultures grown to an OD600nm 708 
of 2.5. In comparison, our samples, which were retrieved at an OD600nm of 2.0, were 709 
grown in AB-minimal medium supplemented with 0.5 % Casamino acids. Despite this, 710 
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we suggest that either the Hfq protein or the RNA RsmY may constitute a possible target 711 
of ajoene. Ajoene effects on lasB transcription as monitored by RT-PCR and DNA array 712 
analysis show only a minor effect in contrast to the observed effects on on lasB-gfp 713 
expression. We see a strong reduction of fluorescence with the lasB-gfp reporter with 714 
increasing ajoene concentrations. The reporter strain is a translational fusion and reflects 715 
the reported effect of the small regulatory RNA molecules on post-transcriptional levels 716 
(as reported as reduction in elastase production by (66)). This is in support of our 717 
hypothesis of ajoene targeting Hfq and the regulatory RNA’s and the effect on 718 
transcription of the lower parts of QS hierarchy is mediated by reduction in BHL 719 
concentration. Furthermore, no effect on the transcription of lasI and rhlI is found on the 720 
transcriptomic analysis, which supports the view that ajoene reducing effect on RhlI 721 
expression is posttranscriptional. The much more pronounced effect of garlic extracts on 722 
a multitude of QS-controlled gene expression reported by us previously (58) taken 723 
together with our shortcomings in the extraction of hydrophilic compounds suggests that 724 
garlic may in fact contain a multitude of QSI compounds or stabilizing agents that may 725 
act in synergy and thereby in concert cover a much larger spectrum of QS controlled 726 
virulence gene expression. If true, food attainable quantities of garlic in the diet may in 727 
fact contribute to a natural prophylaxis against bacterial infections. 728 
 729 
To address the question whether synthesized ajoene constitutes a pharmaceutically 730 
relevant drug candidate, we investigated toxicity effects on human epithelium cells. 731 
Ajoene exerts pro-apoptotic, anti-proliferative and cytotoxic effects on A549 lung 732 
epithelial cells. The concentrations showing half-maximal effects in our assays were in 733 
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the range of 23-46 μg/ml (100-200 μM). Compared to tetrandrine, a substance used as a 734 
lung therapeutic agent in Chinese medicine, ajoene is clearly less toxic (by a factor of 10) 735 
towards respiratory epithelial cells. Interestingly, ajoene is less toxic for A549 cells than 736 
for HL-60 leukemia cells, which respond by intense apoptosis already at concentrations 737 
in the range of 4.7 μg/ml (20 μM) (23). In comparison, the concentration we used in the 738 
mouse experiments was 25 μg/g (107 μM). To more thoroughly evaluate the potential of 739 
ajoene as a putative component of future CF medicine, it will be important to compare its 740 
cytotoxic effects with those induced by antibiotics administered in the treatment of the 741 
CF syndrome.  742 
 743 
In conclusion, we have demonstrated the use of synthetic ajoene to attenuate virulence of 744 
P. aeruginosa by lowering expression of important QS-controlled virulence genes in P. 745 
aeruginosa. It is shown for the first time that successful antimicrobial treatments with the 746 
QS systems as target can be obtained by inhibiting only a few, but important virulence 747 
genes and not the entire QS regulon (mediated through LasR and RhlR). This new finding 748 
leads us to suggest that within the framework of QS inhibition as an antimicrobial 749 
strategy small regulatory RNA molecules operating in the lower part of the QS hierarchy 750 
may constitute a new, functional antimicrobial drug target. At the present, this possible 751 
novel antimicrobial target needs to be extensively pursued and confirmed by molecular 752 
approaches. Interestingly, small regulatory RNA’s or microRNAs and their cognate 753 
targets are strongly implicated in cancer, either as oncogenes or tumor and metastasis 754 
suppressors. Targeting small regulatory RNAs towards therapeutic antimicrobial ends 755 
would therefore parallel future developments in anticancer therapy with cancer-specific 756 
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miRNAs to be exploited not only to produce a direct anticancer effect but also to improve 757 
the response of tumor cells to conventional treatments (35, 69). Similarly, the biofilm 758 
weakening properties of ajoene with respect to enhancing the effect of conventional 759 
antibiotics such as tobramycin may become instrumental for the future development of 760 
combinatory treatments. It is worth to acknowledge that QS-inhibition does not remove 761 
the P. aeruginosa capability of forming a biofilm. However, all available data indicate 762 
that a QS-deficient biofilm is more fragile compared to the QS proficient biofilm (6). 763 
Since for example the matrix component DNA is missing (matrix production is C4-HSL-764 
RhlR controlled) the biofilm is sensitive to shear forces and can slough off dependent on 765 
the hydrodynamic forces. In addition, since rhamnolipid is not formed, the biofilm 766 
becomes sensitive to the action of PMNs (because the PMNs are not killed when they get 767 
in contact with the biofilm). We have previously shown that in vitro biofilms of QS 768 
deficient bacteria can be phagocytosed by freshly isolated PMNs in contrast to QS 769 
proficient biofilms (6). Central in our model for biofilm tolerance to PMNs is that 770 
rhamnolipid production forms a protective shield against the incoming PMNs and we 771 
have several data supporting this (1, 36, 71). Using QSIs should therefore greatly enhance 772 
the antimicrobial properties of the PMNs and allow them to efficiently eradicate biofilm-773 
forming bacteria. Furthermore, rhamnolipid lyses the PMNs that subsequently spill out 774 
their content of DNA, hydrolytic enzymes and oxygen radicals. This creates an “evil 775 
circle” particularly with respect to tissue damage, increasing inflammation and induction 776 
of mutations in P. aeruginosa for which the appearance of the mucoid phenotype 777 
significantly contributes to exacerbations. The key thing is that this should never happen 778 
and a QS-inhibitory drug should prevent this from happening. Our animal experiments 779 
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with clinical isolates suggest that late mucoid isolates are not sensitive to the blocking of 780 
QS-controlled phenotypes whereas early isolates are likely to show sensitivity. Ajoene 781 
might be able to prevent initial adherence and colonization of P. aeruginosa and this 782 
treatment strategy might prevent the chronic lung infection by mucoid strains of P. 783 
aeruginosa in CF patients. The decrease in infection in the mouse experiments, the 784 
removal of in vitro biofilms in a combinatorial experiment with tobramycin and the initial 785 
toxicity test with ajoene suggests the potential of using ajoene as a future antipathogenic 786 
drug for treatment of chronic P. aeruginosa infections. 787 
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Figure legends: 1062 
Fig. 1: 1. Ajoene, present in two isomers; (E) and (Z). 2-5. Ajoene derivatives. 1063 
 1064 
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Fig. 2: Expression of QS controlled specific fluorescence (Gfp expression/cell density). 1065 
The QS bioassays used were P. aeruginosa harboring either the rhlA-gfp or the lasB-gfp 1066 
fusion and E.coli harboring the luxI-gfp fusion incubated with synthesized ajoene.  1067 
 1068 
Fig. 3: Fold change in gene expression of rhlA and lasB measured by RT-PCR (dark grey 1069 
bars) and DNA microarray (light grey bars). Data represent the average of tree individual 1070 
experiments. * indicates P<0.05, Student’s t-test. Error bars are mean ± SD. 1071 
 1072 
Fig. 4: Total rhamnolipid concentration in untreated (no add) and ajoene treated 1073 
planktonic grown P. aeruginosa. The cultures were grown in medium supplemented with 1074 
10 µg/ml, 20 µg/ml, 40 µg/ml and 80 µg/ml of ajoene (rhamnolipid is below the detection 1075 
level for the 40 µg/ml and 80 µg/ml ajoene treatment at OD=1.5). Samples retrieved at 1076 
OD600=1.5 (dark gray bars), and at OD600=2.0 (light grey bars). Data represent the 1077 
average of tree individual experiments. Error bars are mean ± SD. 1078 
 1079 
Fig. 5: Concentrations of C4-HSL and 3-oxo-C12-HSL in untreated (no add) and ajoene 1080 
treated planktonic grown cultures of P. aeruginosa. The cultures were grown in medium 1081 
supplemented with 10 µg/ml, 20 µg/ml, 40 µg/ml and 80 µg/ml of ajoene. Samples 1082 
retrieved at OD600=1.5 (dark gray bars), at OD600=1.8 (light grey bars), and at OD600=2.0 1083 
(medium grey bars). 1084 
 1085 
Fig. 6: Combined fluorescence and light microscopic investigations of biofilms of P. 1086 
aeruginosa exposed to PMNs (arrow) at day four for 180 min at 37°C and then 1087 
 49
subsequently stained with the DNA stain PI. A) The biofilm has grown without ajoene in 1088 
the medium. B) The biofilm has grown in the presence of 100 µg/mL ajoene in the 1089 
medium. Red fluorescence indicates lysed PMNs and green fluorescence indicates P. 1090 
aeruginosa biofilm.  1091 
 1092 
Fig. 7: Biofilms of P. aeruginosa PAO1 (green) (A) and a clinical P. aeruginosa isolate 1093 
CF438 (green, stained with syto9) (B) at day four after 24 h with 10 µg/ml tobramycin or 1094 
100 µg/ml ajoene treatment for 4 days and a combination of tobramycin/ajoene. Dead 1095 
cells are stained with the DNA stain PI (red). The yellow colour reflects a mixture of live 1096 
and dead cells. The biofilm were visualized with confocal scanning laser microscopy. 1097 
 1098 
Fig. 8: Combined results of three separate experiments of ajoene treatment versus no 1099 
treatment (placebo) using the pulmonary infectious mouse model. The BALB/c mice 1100 
were intracheally challenged (at day 0) with alginate beads containing 1.5x108 CFU/ml P. 1101 
aeruginosa. The two groups of mice were either untreated (placebo) or treated with 1102 
ajoene 25μg/g BW once a day. The mice were given two days of prophylactic treatment 1103 
or placebo. Mice were sacrificed on day one or day three post-infection and the contents 1104 
of bacteria in the lungs were determined. The median values are indicated with a filled 1105 
black square. The statistic significance of difference in clearance was tested by a Mann- 1106 
Whitney U test (analysis of nonparametric data) and p-values for the difference at day 1107 
one and day three were 0.9 and 0.002 respectively. 1108 
 1109 
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Table 1: Alterations in gene expression by ajoene. Genes included are >5 times down 1110 
regulated by 80 µg/ml ajoene treatment. The numbers are fold change in gene expression 1111 
compared to an untreated control. Data represent the average of tree individual 1112 
experiments. * Indicates P<0.05, ** indicates P<0.01, Student’s t-test.  1113 
   Ajoene μg/ml 
Gene 
number Gene Description 10 20 40 80 
PA0852 cbpD Chitin-binding protein -2.8  -2.5  -3.9 * -6.9 * 
PA1871 lasA LasA protease precurser -2.6  -2.2  -3 ** -8.7 ** 
PA2069  probable carbamoyl transferase -2.3  -2.4  -4  -5.3 * 
PA2146  Conserved hypothetical protein -1.3  -1.8 * -2.6 * -7.3 ** 
PA2300 chiC Chitinase -2.5  -2.1 * -5.1 ** -24.6 ** 
PA2570 pa1L LecA -1.8  -2  -3.3  -6.3 * 
PA3478 rhlB Rhamnosyltransferase chain B -2.6  -2  -3.3 ** -8.7 ** 
PA3479 rhlA Rhamnosyltransferase chain A -2.2  -1.5  -2.6  -8.8 ** 
PA4141  Hypothetical protein -1   1.1   -1.3  -5.4 ** 
PA4142  probable secretion protein -2  -2.2  -2.7  -5.1 * 
PA4175 prpL Pvds-regulated endoprotease -3.7  -3.3  -5.3 * -6.8 * 
 1114 








